Research Hub

⚠ All information is sourced from peer-reviewed published research. Products sold by BioTemp are for laboratory research use only and are not intended for human consumption, diagnosis, or treatment.

Research Hub

Peer-reviewed comparative analysis of research peptides used in laboratory investigations. Molecular profiles, mechanisms of action, and PubMed-sourced findings for each compound.

GLP-1 Agonists: Semaglutide vs. Tirzepatide

Semaglutide Semaglutide

GLP-1 Receptor Agonist β€’ Single Agonist

MW: 4,113.58 g/mol
CAS: 910463-68-2
Half-Life: ~7 days
Target: GLP-1R
Doses: 2mg, 5mg

GLP-1 analog activating glucose-dependent insulin secretion, gastric slowdown, and appetite suppression. STEP-1: 15–17% weight reduction at 68 weeks (2.4mg weekly).

View Product β†’

Tirzepatide Tirzepatide

GIP/GLP-1 Dual Agonist

MW: 4,813.5 g/mol
CAS: 2023788-19-2
Half-Life: ~5 days
Target: GIP-R + GLP-1R
Doses: 5mg, 10mg

Dual GIP/GLP-1 mechanism producing greater appetite suppression. SURMOUNT-1: 20–22.5% at 72 weeks. 2025 meta-analysis: 4.23% greater loss vs semaglutide (p<0.01).

View Product β†’
Research Note: Tirzepatide's dual-receptor mechanism may offer distinct advantages in metabolic pathway investigations vs single-receptor agonists.

Triple vs. Single: Retatrutide vs. Semaglutide

Retatrutide Retatrutide

Triple Agonist (GLP-1/GIP/Glucagon)

Also: LY3437943
Targets: GLP-1R + GIP-R + GcgR
Class: Next-generation
Status: Phase 3
Doses: 2mg, 5mg

Triple-receptor agonist. Glucagon enhances thermogenesis and fat oxidation. Phase 2 (Jastreboff, NEJM 2023): 24.2% at 48 weeks (12mg) – highest GLP-1 class trial result.

View Product β†’
Semaglutide

Semaglutide

Single Agonist (GLP-1)

MW: 4,113.58 g/mol
CAS: 910463-68-2
Half-Life: ~7 days
Target: GLP-1R only
Doses: 2mg, 5mg

GLP-1 benchmark for isolating single-pathway effects. STEP-1: 15–17% at 68 weeks. Retatrutide exceeded by ~10 points, showing triple-agonist impact.

View Product β†’
Research Note: Retatrutide enables study of combined GLP-1, GIP, and glucagon receptor activation – not possible with semaglutide or tirzepatide alone.

Anti-Inflammatory Peptides: BPC-157 vs. KPV

BPC-157

BPC-157

Synthetic Pentadecapeptide · 15 Amino Acids

Derived From: Human gastric juice proteins
MW: 1,419.5 g/mol
CAS: 137525-51-0
Mechanism: VEGFR2, Akt-eNOS signaling
Doses: 5mg, 10mg

BPC-157 activates VEGFR2 and nitric oxide synthesis via Akt-eNOS, reducing inflammatory cytokines while promoting angiogenesis and tissue repair. Systematic review of 544 studies (1993-2024) found BPC-157 enhances GH receptor expression across muscle, tendon, ligament, and bone injury models.

View Product β†’
KPV

KPV

Tripeptide · Lys-Pro-Val

Derived: Ξ±-MSH C-terminal
MW: 342.43 g/mol
CAS: 27214-00-2
Mechanism: NF-ΞΊB inhibition via PepT1
Doses: 5mg, 10mg

KPV inhibits NF-ΞΊB activation intracellularly after PepT1 uptake, suppressing pro-inflammatory cytokines independent of melanocortin receptors. KPV exerts stronger anti-inflammatory effects than Ξ±-MSH itself. Oral administration reduced inflammation in DSS and TNBS colitis models.

View Product β†’
Research Note: BPC-157 works extracellularly (VEGFR2, ERK1/2). KPV works intracellularly (PepT1, NF-ΞΊB). Complementary mechanisms for different inflammation pathways.

Cellular Repair & Longevity: GHK-Cu vs. NAD+

GHK-Cu

GHK-Cu

Copper Tripeptide · Gly-His-Lys

Discovered: 1973 (human plasma)
MW: 340.38 g/mol
CAS: 49557-75-7
Mechanism: Cu²⁺ binding β†’ 4,000+ gene modulation
Doses: 50mg, 100mg

GHK-Cu binds copper and activates fibroblast proliferation, collagen/elastin synthesis, VEGF/bFGF upregulation. Modulates 4,000+ genesβ€”essentially resetting aging cells toward healthier expression. Collagen increased 9-fold in rat wound models. Declines naturally with age.

View Product β†’
NAD+

NAD+

Coenzyme · Redox Cofactor

Type: Coenzyme
MW: 663.43 g/mol
CAS: 53-84-9
Mechanism: Sirtuin & PARP activation
Doses: 500mg, 1000mg

NAD+ is electron carrier for sirtuins (SIRT1-7) and PARP, governing DNA repair and mitochondrial function. Declines with aging. NMN-mediated elevation activates sirtuins/autophagy, suppresses senescence, accelerates fibroblast wound healing. Shows longevity benefits in aging animal models.

View Product β†’
Research Note: GHK-Cu addresses extracellular matrix degradation. NAD+ addresses cellular energy and DNA repair. Complementary longevity angles.

Growth vs. Cognitive: CJC-1295 vs. Semax

CJC-1295

CJC-1295

GHRH Analogue · GH Secretagogue

Also: DAC:GRF
Amino Acids: 29 (mod. GHRH 1-29)
Half-Life: 5.8-8.1 days
Mechanism: GHRH β†’ GH/IGF-1 elevation
Doses: 2mg, 5mg

CJC-1295 binds GHRH receptors to stimulate GH synthesis. DAC modification extends half-life to ~8 days. Single injection: 2-10x GH for 6+ days, 1.5-3x IGF-1 for 9-11 days. Multiple doses maintain IGF-1 elevation 28+ days with preserved GH pulsatility.

View Product β†’
Semax

Semax

ACTH(4-10) Analogue · Neuropeptide

Sequence: Met-Glu-His-Phe-Pro-Gly-Pro
Amino Acids: 7
Approved: Russia (1996)
Mechanism: BDNF/TrkB & monoamines
Doses: 15mg, 30mg

Semax is ACTH(4-10) with C-terminal Pro-Gly-Pro extension for enzymatic resistance. Upregulates BDNF/TrkB in hippocampus, modulates serotonin/dopamine, activates neuroplasticity. Single 50ΞΌg/kg dose: 1.4x BDNF, 3x BDNF mRNA, improved cognition in models.

View Product β†’
Research Note: CJC-1295 targets somatotropic axis (GH/IGF-1, anabolic). Semax targets CNS (BDNF, neuroprotection). Separate research disciplines.

All citations link to PubMed, NIH, or peer-reviewed journals. For research use only.

Press ESC to close Β· Use ↑↓ to navigate
Scroll to Top
Cart